Cyclooxygenase enzymes: Regulation and function

Current Pharmaceutical Design

Volumn 10, Issue 6, 2004, Pages 577-588

  Fitzpatrick, Frank A ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FENAMIC ACID DERIVATIVE; FLURBIPROFEN; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; N ACETYLIMIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; O (2 METHYLBUTYLOXYPHENYL)HEPT 2 YNYLSULFIDE; O (2 PROPIONYLOXYPHENYL)HEPT 2 YNYLSULFIDE; O (ACETOXYPHENYL)HEPT 2 YNYLSULFIDE; PEROXIDASE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SALICYLIC ACID; SULFONE DERIVATIVE; THROMBOXANE; UNCLASSIFIED DRUG;

CANCER; CANCER PREVENTION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CATALYSIS; CHEMOPROPHYLAXIS; DEGENERATIVE DISEASE; DRUG ACETYLATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEVER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATORY DISEASE; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PEROXIDASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1442301515     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453144     Document Type: Review

References (139)

1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16.
2. Lettino M, Cantu F, Mariani M. Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system. Dig Liver Dis 2001; 33: Suppl 2:S12-20.
3. Graham SH, Hickey RW. Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death. Arch Neurol 2003; 60: 628-30.
4. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002; 110: 33-4.
5. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108:15-23.
6. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 2002; 69: Suppl 1:SI31-9.
7. Kniss DA. Cyclooxygenases in reproductive medicine and biology. J Soc Gynecol Investig 1999; 6: 285-92.
8. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
9. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-82.
10. Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 2001; 11: 752-60.
11. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
12. Isakson P, Seibert K, Masferrer J, Salvemini D, Lee L, Needleman P. Discovery of a better aspirin. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 49-54.
13. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999; 9:1773-8.
14. Elwood PC. Aspirin: past, present and future. Clinical Medicine 2001; 1: 132-137.
15. Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002; 68:115-28.
16. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999; 274: 22903-6.
17. Nugteren DH, Van Dorp DA, Bergstrom S, Hamberg M, Samuelsson B. Absolute configuration of the prostaglandins. Nature 1966; 212: 38-9
18. Nugteren DH, van Dorp DA. The participation of molecular oxygen in the biosynthesis of prostaglandins. Biochim Biophys Acta 1965; 98: 654-6.
19. Lands WE, Samuelsson B. Phospholipid precursors of prostaglandins. Biochim Biophys Acta 1968; 164: 426-9.
20. Nugteren DH, Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biopbys Acta 1973; 326: 448-61.
21. Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxide. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci USA 1974; 71: 3824-8.
22. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol 1971; 231: 237-9.
23. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
24. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
25. Smith WL, Lands WE. Stimulation and blockade of prostaglandin biosynthesis. J Biol Chem 1971; 246: 6700-2.
26. Smith WL, Lands WE. Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochemistry 1972; 11:3276-85.
27. Rome LH, Lands WE. Properties of a partially-purified preparation of the prostaglandin-forming oxygenase from sheep vesicular gland. Prostaglandins 1975; 10: 813-24.
28. Hemler M, Lands WE. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976; 251: 5575-9.
29. Van der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 1977; 487: 315-31
30. Marnett LJ, Wilcox CL. Stimulation of prostaglandin biosynthesis by lipoic acid. Biochim Biophys Acta 1977; 487: 222-30.
31. Egan RW, Humes JL, Kuehl FA Jr. Differential effects of prostaglandin synthetase stimulators on inhibition of cyclooxygenase. Biochemistry 1978; 17: 2230-4.
32. Hemler ME, Crawford CG, Lands WE. Lipoxygenation activity of purified prostaglandin-forming cyclooxygenase. Biochemistry 1978; 17:1772-9.
33. Smith WL, Lands WE. Oxygenation of unsaturated fatty acids by soybean lipoxygenase. J Biol Chem 1972; 247: 1038-47.
34. Setty BN, Stuart MJ, Walenga RW. Formation of 11-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid in human umbilical arteries is catalyzed by cyclooxygenase. Biochim Biophys Acta 1985; 833: 484-94.
35. Thuresson ED, Lakkides KM, Smith WL. Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products. J Biol Chem 2000; 275: 8501-7.
36. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992; 267: 21438-45.
37. Thuresson ED, Lakkides KM, Rieke CJ, Sun Y, Wingerd BA, Micielli R, et al. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem 2001; 276: 10347-57.
38. Malkowski MG, Ginell S, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000; 289: 1933-1937.
39. Kiefer JR, Pawlitz JL, Moreland KT, Stegeman RA, Hood WF, Gierse JK, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000; 405: 97-101.
40. Karthein R, Dietz R, Nastainczyk W, Ruf HH. Higher oxidation states of prostaglandin H synthase. EPR study of a transient tyrosyl radical in the enzyme during the peroxidase reaction. Eur J Biochem 1988; 171: 313-320.
41. Smith WL, Eling TE, Kulmacz RJ, Marnett LJ, Tsai A. Tyrosyl radicals and their role in hydroperoxide-dependent activation and inactivation of prostaglandin endoperoxide synthase. Biochemistry 1992; 31: 3-7.
42. Kulmacz RJ, Pendleton RB, Lands WE. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J Biol Chem 1994; 269: 5527-36.
43. Chen YN, Bienkowski MJ, Marnett LJ. Controlled tryptic digestion of prostaglandin H synthase. Characterization of protein fragments and enhanced rate of proteolysis of oxidatively inactivated enzyme. J Biol Chem 1987; 262: 16892-9.
44. Marnett LJ, Chen YN, Maddipati KR, Ple P, Labeque R. Functional differentiation of cyclooxygenase and peroxidase activities of prostaglandin synthase by trypsin treatment. Possible location of a prosthetic heme binding site. J Biol Chem 1988; 263: 16532-5.
45. Raz A, Needleman P. Differential modification of cyclo-oxygcnase and peroxidase activities of prostaglandin endoperoxidase synthase by proteolytic digestion and hydroperoxides. Biochem J 1990; 269: 603-7.
46. Kulmacz RJ. Concerted loss of cyclooxygenase and peroxidase activities from prostaglandin H synthase upon proteolytic attack. Prostaglandins 1989; 38: 277-88.
47. Markey CM, Alward A, Weller PE, Marnett LJ. Quantitative studies of hydroperoxide reduction by prostaglandin H synthase. Reducing substrate specificity and the relationship of peroxidase to cyclooxygenase activities. J Biol Chem 1987; 262: 6266-79.
48. Tsai A, Palmer G, Xiao G, Swinney DC, Kulmacz RJ. Structural characterization of arachidonyl radicals formed by prostaglandin H synthase-2 and prostaglandin H synthase-1 reconstituted with mangano protoporphyrin IX. J Biol Chem 1998; 273: 3888-94.
49. Kulmacz RJ, Wang LH. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 1995; 270: 24019-23.
50. Lu G, Tsai AL, Van Wart HE, Kulmacz RJ. Comparison of the peroxidase reaction kinetics of prostaglandin H synthase-1 and -2. J Biol Chem 1999; 274: 16162-7.
51. Xiao G, Chen W, Kulmacz RJ. Comparison of structural stabilities of prostaglandin H synthase-1 and -2. J Biol Chem 1998; 273: 6801-11.
52. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A Single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors J Biol Chem 1996; 271: 15810-15814.
53. 2 synthase. Characteristics of mechanism-based inactivation with isolated enzyme and intact platelets. J Biol Chem 1990; 265: 20166-71.
54. 2 synthase: characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Arch Biochem Biophys 1995; 321: 453-8.
55. 3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase. J Biol Chem 1985; 260: 10966-70.
56. 4 formation by human erythrocytes. J Biol Chem 1990; 265: 14911-6.
57. Aharony D, Redkar-Brown DG, Hubbs SJ, Stein RL. Kinetic studies on the inactivation of 5-lipoxygenase by 5(S)-hydroperoxyeicosatetraenoic acid. Prostaglandins 1987; 33: 85-100.
58. 4. Characterization of product inactivation with purified enzyme and intact leukocytes. J Biol Chem 1994; 269: 2627-31.
59. De Carolis E, Denis D, Riendeau D. Oxidative inactivation of human 5-lipoxygenase in phosphatidylcholine vesicles. Eur J Biochem 1996; 235: 416-23.
60. Kishimoto K, Nakamura M, Suzuki H, Yoshimoto T, Yamamoto S, Takao T, et al. Suicide inactivation of porcine leukocyte 12-lipoxygenase associated with its incorporation of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid derivative. Biochim Biophys Acta 1996; 1300: 56-62.
61. Smith WL, Lands WE. The self-catalyzed destruction of lipoxygenase. Biochem Biophys Res Commun 1970; 41: 846-51.
62. Kim MR, Sok DE. Irreversible inhibition of soybean lipoxygenase-1 by hydroperoxy acids as substrates. Arch Biochem Biophys 1991; 288: 270-5.
63. Wiesner R, Suzuki H, Walther M, Yamamoto S, Kuhn H. Suicidal inactivation of the rabbit 15-lipoxygenase by 15S-HpETE is paralleled by covalent modification of active site peptides. Free Radic Biol Med 2003; 34: 304-15.
64. Egan RW, Paxton J, Kuehl FA. Mechanism for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem 1976; 251: 7329-35.
65. 2. Prostaglandins 1977; 14: 881-9.
66. Crutchley DJ, Hawkins HJ, Eling TE, Anderson MW. Covalent binding of prostaglandins G2 and H2 to components of ram seminal vesicle microsomal fraction. Biochem Pharmacol 1979; 28:1519-23.
67. Lecomte M, Lecocq R, Dumont JE, Boeynaems J-M. Covalent binding of arachidonic acid metabolites to human platelet proteins. Identification of prostaglandin H synthase as one of the modified substrates. J Biol Chem 1990; 265: 5178-87.
68. Rapoport S, Hartel B, Hausdorf G. Methionine sulfoxide formation: the cause of self-inactivation of reticulocyte lipoxygenase. Eur J Biochem 1984; 139: 573-6.
69. Boutaud O, Brame CJ, Chaurand P, Li J, Rowlinson SW, Crews BC, et al. Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid. Biochemistry 2001; 40: 6948-55.
70. 2 synthase-dependent pathway after platelet activation. J Biol Chem 2003; 278: 16926-8.
71. Bernoud-Hubac N, Roberts LJ. Identification of oxidized derivatives of neuroketals. Biochemistry 2002; 41:11466-71.
72. Wu G, Wei C, Kulmacz RJ, Osawa Y, Tsai AL. A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1. J Biol Chem 1999; 274: 9231-7.
73. Song I, Ball TM, Smith WL. Different suicide inactivation processes for the peroxidase and cyclooxygenase activities of prostaglandin endoperoxide H synthase-1. Biochem Biophys Res Commun 2001; 289: 869-75.
74. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-6.
75. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspitin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983; 22: 4672-5.
76. Van Der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 1980; 109:1-8.
77. Wells I, Marnett LJ. Acetylation of prostaglandin endoperoxide synthase by N-acetylimidazole: comparison to acetylation by aspirin. Biochemistry 1992; 31: 9520-5.
78. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72:1177-84.
79. Patrono C. Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity. Clin Exp, Rheumatol 2001; 19: (6 Suppl 25): S45-50.
80. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001; 110: 62S-65S.
81. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301: 577-9
82. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: (8607), 349-60.
83. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Brit Med J 2001; 316: 1337-43.
84. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998; 280:1268-70.
85. Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP, Marnett LJ. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem 1998; 41: 4800-18.
86. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-44.
87. Schneider C, Brash AR. Stereospecificity of hydrogen abstraction in the conversion of arachidonic acid to 15R-HETE by aspirin-treated cyclooxygenase-2. Implications for the alignment of substrate in the active site. J Biol Chem 2000; 275: 4743-6.
88. Lecomte M, Laneuville O, Ji C, DeWitt DL, SmithWL. Acetylation of human rostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-15.
89. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C, Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997; 48: 623-31.
90. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-4.
91. Trummlitz G, van Ryn J. Designing selective COX-2 inhibitors: molecular modeling approaches. Curr Opin Drug Discov Devel 2002; 5: 550-61.
92. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003; 63: 33-45.
93. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-9.
94. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
95. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8.
96. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996; 3: 927-33.
97. Lin AH, Bienkowski MJ, Gorman RR. Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J Biol Chem 1989; 264: 17379-83.
98. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-41.
99. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
100. FitzGerald GA, Reilly IA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194-201.
101. Nowak J, FitzGerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 1989; 83: 380-5.
102. 4 by transcellular biosynthesis. Proc Natl Acad Sci USA 1986; 83: 1349-53.
103. 4. J Biol Chem 1088; 263: 174-181.
104. 4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986; 261: 16466-72.
105. Bailey JM, Muza B, Hla T, Salata K. Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. J Lipid Res 1985; 26: 54-61.
106. 2 biosynthesis in platelet-free human monocytes and the possible role of polypeptide growth factor(s) in the induction of cyclooxygenase system. Biochim Biophys Acta 1986; 876: 486-93.
107. O'Neill LA, Barrett ML, Lewis GP. Induction of cyclooxygenase by interleukin-1 in rheumatoid synovial cells. FEBS Lett 1987; 212: 35-9.
108. Pash JM, Bailey JM. Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J 1988; 2: 2613-8.
109. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
110. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40.
111. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375-9.
112. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-21.
113. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001; 276: 12440-8.
114. Guan Z, Baier LD, Morrison AR. p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1beta. J Biol Chem 1997; 272: 8083-9.
115. Newton R, Seybold J, Kuitert LM, Bergmann M, Barnes PJ. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 1998; 273: 32312-21.
116. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000; 275: 11750-7.
117. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP. Aberrant methylation of the cyclooxygenase-2 CpG island in colorectal tumors. Cancer Res 2000; 60: 4044-8.
118. Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, et al. Transcriptional silencing of cyclooxygenase-2 by hypermethylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res 2001; 61: 4628-35.
119. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-20.
120. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645.
121. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 519-25.
122. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-4.
123. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-90.
124. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823-6.
125. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-8.
126. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
127. Kulmacz RJ. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett 1998; 430:154-7.
128. Marshall PJ, Kulmacz RJ, Lands WE. Constraints on prostaglandin biosynthesis in tissues. J Biol Chem 1987; 262: 3510-7.
129. Lands WE, Sauter J, Stone GW. Oxygen requirement for prostaglandin biosynthesis. Prostaglandins Med 1978; 1: 117-20.
130. Goodwin DC, Landino LM, Marnett LJ. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J 1999; 13: 1121-36.
131. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J. 2002; 324: 1287-8.
132. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89: 26D-32D.
133. Reuter BK, Zhang XJ, Miller MJ. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2002; 2: 19.
134. Sansom OJ, Stark LA, Dunlop MG, Clarke AR. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res 2001; 61: 7060-4.
135. Williamson SL, Kartheuser A, Coaker J, Kooshkghazi MD, Fodde R, Burn J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 1999; 20: 805-10.
136. Trifan OC, Smith RM, Thompson BD, Hla T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem 1999; 274: 34141-7.
137. Baraldi PG, Cacciari B, Borean PA, Varanin K, Pastorin G, Da Ros T, et al. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Curr Pharm Design 2002; 8(26): 2299-332.
138. Oshima M, Taketo MM. COX selectivity and animal models for colon cancer. Curr Pharm Design 2002; 8(12): 1021-34.
139. Rodriguez-Tellez M, Arguelles F, Herrerias JM Jr, Ledro D, Esteban J, Herrerias JM. Antiinflamatory agents less dangerous for gastrointestinal tract. Curr Pharm Design 2001; 7(10): 951-76.